You are on page 1of 8

ISAM symposium

Updates and Controversies Related


to Inhaled Aerosols

Friday May 18, 2018

University of California, San Diego


(Village 15, rooms 15A/15B)
Welcome message

The organizing committee of the 2018 ISAM symposium is pleased to welcome


you in La Jolla, CA, for a one-day program focused on “Updates and
Controversies Related to Inhaled Aerosols”. The goal of this symposium is to
bring together industry, academic and regulatory scientists as well as clinicians
and fellows in a dynamic environment to review/discuss/debate a wide range
of topics including E-cigarette and their impact on pulmonary health, updates
on bronchial challenge testing, controversies on inhaled antibiotics, inhaled
therapies in the era of digital health, and personalized medicine.

The program has been designed to allow the attendees time to interact with
our corporate sponsors, and for attendees to network in an engaging setting.

This symposium is supported by contributions from the following companies:

Gold
sponsor:

Bronze
sponsor:

Other
sponsor:

Program Committee: Chantal Darquenne and Rui C Sá (University of


California, San Diego), James Fink (Aerogen Pharma Corporation), Otmar
Schmid (Comprehensive Pneumology Center, Helmholtz Zentrum München)
and Philip Kuehl (Lovelace Respiratory Research Institute).

2
Meeting Place

University of California, San Diego


15th floor of Village West building 1
Rooms 15-A/15-B
Corner of UCSD Northpoint Driveway & Scholar Drive N

Room 15-C
Marye Anne Fox Executive Conference Room Room 15-B Room 15-A
Emergency Exit

Credenza Catering Tables


Catering Tables
Credenza

Projector Screen
Credenza

Emergency Exit

Credenza
Men’s Ladies
Lobby Restroom Restroom Pantry Storage
Elevators

Credenza

Emergency Exit

UCSD Northpoint UCSD venue:


Driveway The Village
West Building 1
Visitor Parking 15th floor

Scholar Dr N

3
Program

8:30 am: Registration


9:00 am: Welcome
Chantal Darquenne (La Jolla, CA/US)
9:10 am: Morning session 1: E-cigarettes (Room 15-A)
Chair: Otmar Schmid (Munich, Germany)
9:10 am: Understanding the quantitative relationship between e-cigarette use behavior
and exposure
Risa Robinson (Rochester, NY/US)
9:35am: Intrapulmonary Deposition & Uptake Kinetics of Electronic Cigarette Vapor
Imaged with PET
Jose Venegas (Boston, MA/US)
9:50am: Carbonyl’s in electronic cigarette emissions, are we accurately measuring
them and do they matter?
Philip Kuehl, PhD (Albuquerque, NM/US)
10:05 am: Coffee break (Room 15-B)
10:35 am: Morning session 2: Updates on bronchial challenge testing (Room 15-A)
Chair: Chantal Darquenne (La Jolla, CA/US)
10:35 am: Bronchial Challenge testing: a clinical perspective
Donald W Cockcroft (Saskatoon, Saskatchewan, Canada)
11:00 am: Methacholine bronchoconstriction is spatially persistent and independent of
posture during drug inhalation
Eric Geier (La Jolla, CA/US)
11:15 am: Bronchial Challenge testing in preclinical studies
Otmar Schmid (Munich, Germany)
11:40 am: Morning session 3: Pro/Con debate: Should we use inhaled antibiotics
to treat non-cystic fibrosis bronchiectasis? (Room 15-A)
Chair: James Fink (San Mateo, CA/US)
11:40am: Pro: We should use inhaled antibiotics to treat non-cystic fibrosis
bronchiectasis?
David Cipolla (Hayward, CA/US)
12:00pm: Con: We should not use inhaled antibiotics to treat non-cystic fibrosis
bronchiectasis?
Andrew Clark (San Mateo, CA/US)
12:20pm: rebuttal/vote

4
12:30 pm: Lunch (Room 15-B, Patio)
1:30 pm: Afternoon session 1: Personalized medicine: which device is best for
your patient? (Room 15-A)
Chair: Rui C. Sá (La Jolla CA/US)
1:30pm: Personalized medicine: which device is best for your patient?
Arzu Ari (San Marcos, TX/US)
1:55pm: Justification of the Inhalation Parameters to Provide Patients with Dose
Confirmation Feedback When They Use a Digitally Enabled Albuterol
Multidose Dry Powder Inhaler (eMDPI).
Gui Safoti (Amsterdam, Netherlands)
2:10pm: Enabling Aerosol Delivery to Our Smaller Patients: Developing Drugs for
Infants
James Fink (San Mateo, CA/US)
2:25 pm: Afternoon session 2: Industry-sponsored session
Panel discussion - Can aerosol therapy benefit from digital health?
(Room 15-B)
Facilitator: Philip Kuehl (Albuquerque, NM/US)
2:25 pm: Aerosol therapy and digital health: a clinician’s perspective
Douglas J Conrad (San Diego, CA/US)
2:45 pm: Panel discussion
Sam van Alstyne (Connected Health - 3M Drug Delivery Systems)
Sai Shankar (Connected Devices, Aptar Pharma)
Douglas J Conrad (Clinician, University of California, San Diego)
3:50 pm: Poster session/ Hands-on demo (Room 15-B)
4:50 pm: Final remarks
Chantal Darquenne (La Jolla, CA/US)
5:00 pm: Reception/Networking (Patio)
7:00 pm: End of symposium

5
POSTERS

Poster 1
Preclinical Experiments Support Recent Clinical Switch to Delivered Dose During
Methacholine Bronchoprovocation Testing. O. Schmid1, W. Möller1, A. Stelzl1, J.
Lund2, A.Ö. Yildirim1, S. Krauss-Etschmann2, A. Robichaud3.
1
Comprehensive Pneumology Center (CPC), Helmholtz Zentrum München (HMGU),
Neuherberg/Munich, Germany, 2 Research Center Borstel (RCB), Borstel, Germany, 3
SCIREQ Scientific Respiratory Equipment, Inc., Montreal, Quebec, Canada.

Poster 2
Methacholine bronchoconstriction is spatially persistent and independent of
posture during drug inhalation. E.T. Geier1, K. Kubo1, I. Neuhart2, R.J. Theilmann3,
G.K. Prisk1, R.C. Sá1
1
Department of Medicine, University of California – San Diego. 2The Ohio State
University. 3Department of Radiology, University of California – San Diego.

Poster 3
Intrapulmonary Deposition & Uptake Kinetics of Electronic Cigarette Vapor Imaged
with PET. Jose G. Venegas, PhD1, Jiayuan Zhao, PhD2, Gabriel Mota-Ribeiro1, Philip
Demokritou PhD2, Mikhail Papisov, PhD3.
1
Department of Anesthesia and Critical Care and Pain Medicine, Massachusetts General
Hospital and Harvard Medical School, Boston, MA, 2 Department of Environmental
Health, Center for Nanotechnology and Nanotoxicology, Harvard School of Public Health,
Boston, MA, 3Department of Radiochemistry, Massachusetts General Hospital and
Harvard Medical School, Boston, MA.

Poster 4
Justification of the Inhalation Parameters to Provide Patients with Dose
Confirmation Feedback When They Use a Digitally Enabled Albuterol Multidose Dry
Powder Inhaler (eMDPI). H. Chrystyn1, G. Safioti2, D. Buck3, F. Ruiter4, J. Blair3.
1
Inhalation Consultancy Ltd, Leeds, United Kingdom, 2Teva Pharmaceutical Industries,
Amsterdam, Netherlands, 3Teva Pharmaceutical Industries, Waterford, Ireland, 4Teva
Pharmachemie, Haarlem, Netherlands.

6
Poster 5
The Accuracy of an Electronic Multidose Dry Powder Inhaler (eMDPI) To Measure
Inhalation Parameters When Used by Patients. H. Chrystyn1, D. Saralaya2, A.
Shenoy2, S. Toor3, K. Kastango4, E. Calderon5, G. Safioti6.
1
Inhalation Consultancy Ltd, Leeds, United Kingdom, 2Bradford Teaching Hospitals NHS
Foundation Trust & Bradford Institute for Health Research, Bradford, United Kingdom,
3
Respiratory Matters, Huddersfield, United Kingdom, 4QuintilesIMS, Cambridge, MA,
United States, 5Teva Pharmaceutical Industries, Waterford, Ireland, 6Teva
Pharmaceutical Industries, Amsterdam, Netherlands.

Poster 6
i-BAN, a unique breath-actuated, small volume, jet nebulizer vs AE II: aerosol
characterization in continuous and breath-actuated mode. Rohinton Toddywala1,
Vijay Shukla1, Akanksha Hande1, Michael Newhouse2.
InspiRx Inc., Somerset NJ, 2McMaster, Faculty of Health Sciences, Hamilton, Canada
1

Poster 7
Compliance with Once-Daily Inhaled Liposomal Ciprofloxacin (ARD-3150) therapy
in Non-cystic Fibrosis Bronchiectasis. Angela Davis1, Igor Gonda2, Juergen
Froehlich2, David Cipolla2.
1
Grifols, Research Triangle Park, NC, 2Aradigm Corporation, Hayward, CA.

Poster 8
Formulation and non-clinical assessment of a novel dry powder formulation of
Topotecan for targeted treatment of lung cancer. Philip J. Kuehl, Michael Burke,
Ramesh Chand, Devon Dubose, June Liu, and Mathewos Tessema.
Lovelace Biomedical, Albuquerque, NM

Poster 9
Bringing Pharmaceutical Science to the Cannabis and Industrial Hemp Industries:
Development of Dry Powders Suitable for Inhalation. Lia Rebits1 and Robert Sievers2.
1
KelSie Biotech LLC, Boulder, CO, 2Dept. of Chemistry and Biochemistry, University of
Colorado, Boulder, CO.

7
Poster 10
A Novel Approach to Controlling Particle Morphology for the Engineering of
Respirable Powders. Xuno Gildelamadrid1 and Robert Sievers2.
1
KelSie Biotech LLC, Boulder, CO, 2Dept. of Chemistry and Biochemistry, University of
Colorado, Boulder, CO.

Poster 11
Aerosol Dosimetry in Asthmatic Airways: An in-Silico Modeling Pilot Study. K.
Poorbahrami1, S. B. Fain2, D. Mummy3, J. M. Oakes4.
Mechanical and Industrial Engineering, Northeastern University, Boston, MA,
1

Departments of Medical Physics and Radiology, School of Medicine and Public Health,
2

University of Wisconsin Madison, Madison, WI,3Medical Physics, University of Wisconsin-


Madison, Madison, WI, 4Bioengineering, Northeastern University, Boston, MA.

Poster 12
Age-Dependent Deposition Patterns and Quantitative Biokinetics of Inhaled 20nm
Gold Nanoparticles in Rat Lungs. J. C. Schittny1, W. Moeller2, U. Holzwarth3, S. Hirn2,
A. Wenk2, C. Schleh2, M. Schäffler2, N. Haberl2, N. Gibson3, W. G. Kreyling2.
1
Inst of Anatomy, Univ of Bern, Bern, Switzerland, 2Institute of Lung Biology and Disease,
Helmholtz Center Munich, Neuherberg/Munich, Germany, 3Consumers and Reference
Materials, European Commission, Joint Research Centre, Directorate for Health, Ispra,
Italy.